Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label trial of HEC53856 versus recombinant human erythropoietin for chemotherapy-induced anemia in patients with non-myeloid malignancies
CTR20263895Phase 2Active
- Sponsor
- HEC Pharm
- Start
- Oct 2026
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HEC53856, erythropoietin in chemotherapy-induced anaemia (CIA), sponsored by HEC Pharm. Started Oct 2026; status: active.
02
Drugs
HEC53856erythropoietin
03
Conditions
chemotherapy-induced anaemia (CIA)
Beyond the preview
Go deeper on CTR20263895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263895.